Study guide
3.2 COPD: Staging, Long-Term Management & Acute Exacerbations
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
3.2 COPD: Staging, Long-Term Management & Acute Exacerbations
Key Takeaways Explain This Topic AI
Diagnosis of COPD requires post-bronchodilator spirometry demonstrating an obstructive FEV1/FVC ratio < 0.70 that does not normalize in an individual with exposure to risk factors (smoking, biomass fuels, occupational dust).
Airflow limitation severity is staged by post-bronchodilator FEV1 percentage predicted: Stage 1 Mild (>= 80%), Stage 2 Moderate (50-79%), Stage 3 Severe (30-49%), and Stage 4 Very Severe (< 30%).
Smoking cessation is the single most effective intervention to slow disease progression and decline in FEV1; non-pharmacological management includes pulmonary rehabilitation for MRC dyspnoea score >= 3 and annual influenza plus pneumococcal vaccinations.
Inhaled maintenance stepping stratifies patients into those without asthmatic features (LABA + LAMA combination) and those with asthmatic features or a higher blood eosinophil count (LABA + ICS), progressing to triple therapy (LAMA + LABA + ICS) if exacerbations persist.
Long-term oxygen therapy (LTOT) confers proven survival benefit in non-smokers with stable resting PaO2 < 7.3 kPa, or PaO2 7.3-8.0 kPa with cor pulmonale, polycythaemia, or pulmonary hypertension; acute exacerbations require controlled oxygen (target SpO2 88-92%) and BiPAP for persistent respiratory acidosis (pH below 7.35 and PaCO2 above 6.5 kPa after optimal medical therapy).
Last updated: October 2026
3.2 COPD: Staging, Long-Term Management & Acute Exacerbations
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable lung condition characterized by persistent, usually progressive airflow limitation associated with an enhanced chronic inflammatory response in the airways and lung parenchyma to noxious particles or gases. Tobacco smoking accounts for over 80% of cases in high-income settings, alongside occupational dust and biomass fuel exposures.
1. Pathophysiology and Clinical Diagnosis
COPD encompasses two distinct but frequently overlapping pathological processes:
Chronic Bronchitis: Clinically defined as a daily productive cough for at least 3 consecutive months in 2 successive years. Pathologically, it involves goblet cell hyperplasia, submucosal gland hypertrophy in large bronchi, and ciliary dysfunction.
Emphysema: Anatomically defined as abnormal, permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls without gross fibrosis. Centrilobular emphysema primarily affects the upper lung lobes in cigarette smokers, whereas panacinar emphysema affects the lower lung lobes and is classically associated with alpha-1 antitrypsin deficiency .
Clinical Presentation
Exertional Dyspnoea: Progressive, persistent, and worsening with exercise.
Chronic Cough: Often productive with clear or white mucoid sputum.
Physical Signs: Wheezing, tachypnoea, hyperinflated "barrel chest" (increased anteroposterior diameter), pursed-lip breathing, intercostal indrawing, reduced cricosternal distance ( < 3 finger breadths < 3\text{ finger breadths} < 3 finger breadths ), and loss of cardiac dullness.
Diagnostic Spirometry
Diagnosis requires post-bronchodilator spirometry performed 15 minutes after inhaling 400 mcg salbutamol:
Diagnostic Threshold: FEV 1 / FVC < 0.70 \mathbf{\text{FEV}_1/\text{FVC} < 0.70} FEV 1 / FVC < 0.70 (a fixed, non-reversible ratio).
The lack of significant reversibility differentiates COPD from asthma, although a subset of patients exhibits asthma-COPD overlap features.
2. Severity Staging by Airflow Limitation
Once an obstructive ratio ( FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 / FVC < 0.70 ) is confirmed, disease severity is graded based on the post-bronchodilator FEV 1 \text{FEV}_1 FEV 1 expressed as a percentage of predicted normal value:
Severity Stage Post-Bronchodilator FEV 1 \text{FEV}_1 FEV 1 (% Predicted) Clinical Characteristics
Stage 1: Mild ≥ 80 % \ge 80\% ≥ 80% predicted Often asymptomatic or mild exertional cough; patient may be unaware of abnormal lung function
Stage 2: Moderate 50 – 79 % 50\text{--}79\% 50 – 79% predicted Shortness of breath on exertion, chronic cough, and sputum production; presentation for medical attention
Stage 3: Severe 30 – 49 % 30\text{--}49\% 30 – 49% predicted Frequent exacerbations, marked reduction in exercise tolerance, significant fatigue, and daily impairment
Stage 4: Very Severe < 30 % < 30\% < 30% predicted (or < 50 % < 50\% < 50% with chronic respiratory failure) Severe dyspnoea at rest or minimal exertion, cor pulmonale, peripheral oedema, respiratory failure
3. Disease-Modifying & Non-Pharmacological Management
Only two therapeutic interventions have been proven in randomized trials to reduce mortality in COPD:
Smoking Cessation: The single most effective intervention to halt accelerated annual decline in FEV 1 \text{FEV}_1 FEV 1 . First-line pharmacotherapies include nicotine replacement therapy (NRT transdermal patch + oral gum/lozenge), varenicline (nicotinic receptor partial agonist), or bupropion.
Long-Term Oxygen Therapy (LTOT): Indicated for selected patients with severe chronic resting hypoxaemia.
Key Non-Pharmacological Interventions
Pulmonary Rehabilitation: A multi-disciplinary programme combining physical exercise training, disease education, and nutritional advice. Proven to reduce hospital readmissions and improve quality of life. Strongly indicated for patients with a Medical Research Council (MRC) dyspnoea scale score ≥ 3 \ge 3 ≥ 3 or following a recent hospital admission for an acute exacerbation.
Vaccinations: Annual inactivated influenza vaccination and pneumococcal vaccination (PCV20 or PPV23) to prevent infective exacerbations.
Alpha-1 Antitrypsin Screening: Recommended by NICE for all patients diagnosed with COPD before age 50 or with minimal smoking history.
4. Stepwise Inhaled Maintenance Therapy (NICE NG115)
Pharmacological treatment aims to reduce symptoms, decrease the frequency and severity of exacerbations, and improve exercise capacity.
Step 1: Initial Symptom Relief
Short-acting beta-2 agonist (SABA, e.g., salbutamol) or short-acting muscarinic antagonist (SAMA, e.g., ipratropium) as needed for transient breathlessness.
Step 2: Maintenance Therapy for Persistent Symptoms / Exacerbations
Patients are stratified according to the presence or absence of asthmatic features or steroid responsiveness (NICE NG115: a previous secure diagnosis of asthma or atopy, a higher blood eosinophil count , substantial variation in FEV 1 \text{FEV}_1 FEV 1 over time (at least 400 mL) or substantial diurnal variation in PEF (at least 20%)). NICE gives no eosinophil cut-off; the international GOLD report uses ≥ 300 cells/ μ L \ge 300\text{ cells/}\mu\text{L} ≥ 300 cells/ μ L as the level that most favours adding an ICS:
Without Asthmatic Features: Prescribe a dual long-acting bronchodilator: LABA + LAMA (e.g., indacaterol/glycopyrronium, vilanterol/umeclidinium).
With Asthmatic Features / Higher Eosinophils (GOLD: ≥ 300 / μ L \ge 300/\mu\text{L} ≥ 300/ μ L ): Prescribe LABA + ICS (e.g., formoterol/budesonide, salmeterol/fluticasone).
Step 3: Triple Therapy
If patients on LABA + LAMA experience subsequent exacerbations ( ≥ 1 \ge 1 ≥ 1 hospital admission or ≥ 2 \ge 2 ≥ 2 moderate exacerbations per year), or patients on LABA + ICS have ongoing symptoms, escalate to Triple Therapy: LAMA + LABA + ICS .
Caution
Inhaled corticosteroid (ICS) monotherapy is contraindicated in COPD. ICS use in COPD carries an increased risk of bacterial pneumonia. It should only be prescribed in combination with a LABA and targeted to patients with documented frequent exacerbations or eosinophilic airway inflammation.
5. Long-Term Oxygen Therapy (LTOT)
Long-term oxygen therapy increases survival and improves haemodynamics in selected patients with severe resting chronic arterial hypoxaemia.
Eligibility Criteria
Assessment must occur when the patient is clinically stable on optimal treatment (British Thoracic Society home oxygen guidance: not within 8 weeks of an exacerbation), using two arterial blood gas measurements at least 3 weeks apart (NICE NG115):
Absolute Threshold: Resting PaO 2 < 7.3 kPa \mathbf{\text{PaO}_2 < 7.3\text{ kPa}} PaO 2 < 7.3 kPa ( < 55 mmHg < 55\text{ mmHg} < 55 mmHg ) on room air.
Relative Threshold: Resting PaO 2 between 7.3 and 8.0 kPa \mathbf{\text{PaO}_2\text{ between } 7.3\text{ and } 8.0\text{ kPa}} PaO 2 between 7.3 and 8.0 kPa ( 55 – 60 mmHg 55\text{--}60\text{ mmHg} 55 – 60 mmHg ) in the presence of any of the following:
Secondary polycythaemia (haematocrit ≥ 55 % \ge 55\% ≥ 55% ).
Clinical or echocardiographic evidence of pulmonary hypertension.
Peripheral oedema suggestive of cor pulmonale.
Strict Requirements for Prescription
Must be administered for at least 15 hours per day , including overnight hours (continuous 24-hour use provides greater survival benefit).
The patient must be a confirmed non-smoker (verified by carbon monoxide breath testing) due to the catastrophic risk of facial burns, home fires, and explosive flash injury.
6. Acute Exacerbation of COPD (AECOPD)
An acute exacerbation is defined as a sustained worsening of the patient's respiratory symptoms beyond normal day-to-day variations that leads to a change in medication.
Cardinal Symptoms (Anthonisen Criteria)
Worsening dyspnoea.
Increased sputum volume.
Increased sputum purulence (green/yellow colour due to myeloperoxidase from neutrophils).
Emergency Management Protocol
Controlled Oxygen Therapy:
Administer controlled oxygen via a 24 % 24\% 24% or 28 % 28\% 28% Venturi mask .
Target Oxygen Saturation: 88 – 92 % \mathbf{88\text{--}92\%} 88 – 92% .
Pathophysiological Rationale: Excessive oxygen delivery suppresses hypoxic drive in chronic CO2 retainers, reverses compensatory hypoxic pulmonary vasoconstriction leading to increased dead-space ventilation (V/Q mismatch), and unloads CO2 from deoxygenated haemoglobin (the Haldane effect), causing severe acute hypercapnic respiratory acidosis and CO2 narcosis.
Nebulised Bronchodilators:
Salbutamol 2.5 – 5 mg 2.5\text{--}5\text{ mg} 2.5 – 5 mg and ipratropium bromide 0.5 mg 0.5\text{ mg} 0.5 mg .
Crucial Safety Rule: Nebulisers in COPD must be driven by compressed air , not high-flow oxygen, to prevent hypercapnia. Supplemental oxygen should be delivered simultaneously via nasal cannulae at 1 – 2 L/min 1\text{--}2\text{ L/min} 1 – 2 L/min to maintain saturations at 88 – 92 % 88\text{--}92\% 88 – 92% .
Systemic Corticosteroids:
Oral prednisolone 30 mg 30\text{ mg} 30 mg once daily for 5 days .
Short courses are equivalent to prolonged regimens and minimize steroid-induced myopathy, osteoporosis, and hyperglycaemia.
Antimicrobial Therapy:
Prescribed when sputum is purulent or when all three cardinal Anthonisen symptoms are present.
First-line oral choices: Amoxicillin 500 mg 500\text{ mg} 500 mg TDS , Doxycycline 200 mg 200\text{ mg} 200 mg stat then 100 mg 100\text{ mg} 100 mg OD , or Clarithromycin 500 mg 500\text{ mg} 500 mg BD for 5 days.
7. Non-Invasive Ventilation (NIV / BiPAP)
Non-invasive positive pressure ventilation (BiPAP) delivers pressurized gas via a tight-fitting facial or nasal mask, decreasing work of breathing, improving alveolar ventilation, and reversing respiratory acidosis.
Indications for NIV
Acute hypercapnic respiratory failure secondary to COPD exacerbation with:
Arterial blood gas showing pH < 7.35 \text{pH} < 7.35 pH < 7.35 and PaCO 2 > 6.5 kPa \text{PaCO}_2 > 6.5\text{ kPa} PaCO 2 > 6.5 kPa (BTS/ICS 2016 acute hypercapnic respiratory failure guideline).
Persisting despite up to 60 minutes of optimal medical therapy (controlled oxygen, nebulisers, systemic steroids, antibiotics if indicated).
Severe acidosis (pH below 7.26) does not by itself rule out NIV, but it should then be delivered in a high-dependency setting with a clear plan for intubation if it fails.
Technical Settings & Goals
Inspiratory Positive Airway Pressure (IPAP): BTS/ICS suggests starting at about 15 cmH 2 O 15\text{ cmH}_2\text{O} 15 cmH 2 O and increasing to 20 – 30 cmH 2 O 20\text{--}30\text{ cmH}_2\text{O} 20 – 30 cmH 2 O within 10–30 minutes as tolerated to improve ventilation and clear CO2.
Expiratory Positive Airway Pressure (EPAP): Typically 3 – 5 cmH 2 O 3\text{--}5\text{ cmH}_2\text{O} 3 – 5 cmH 2 O to recruit collapsed alveoli and counteract intrinsic PEEP.
Repeat ABG at 1 hour after initiating NIV; an improving pH and falling PaCO 2 \text{PaCO}_2 PaCO 2 confirms efficacy.
Clinical Parameter LTOT Criteria (Stable Outpatient) NIV / BiPAP Criteria (Acute Inpatient)
Timing of Assessment Clinically stable (BTS: at least 8 weeks after an exacerbation) Acute exacerbation after 1 hour of medical therapy
Arterial Blood Gas PaO 2 < 7.3 kPa \text{PaO}_2 < 7.3\text{ kPa} PaO 2 < 7.3 kPa (or 7.3 – 8.0 kPa 7.3\text{--}8.0\text{ kPa} 7.3 – 8.0 kPa with cor pulmonale) pH < 7.35 \text{pH} < 7.35 pH < 7.35 and PaCO 2 > 6.5 kPa \text{PaCO}_2 > 6.5\text{ kPa} PaCO 2 > 6.5 kPa
Primary Objective Improve long-term survival and pulmonary vascular pressures Correct acute respiratory acidosis, avoid invasive intubation
Duration / Settings ≥ 15 hours/day \ge 15\text{ hours/day} ≥ 15 hours/day via nasal cannula BiPAP with IPAP about 15 rising to 20 – 30 20\text{--}30 20 – 30 , EPAP 3 – 5 3\text{--}5 3 – 5
Key Contraindication Active cigarette smoking (fire hazard) Severe facial burns/trauma, vomiting, uncooperative/coma, pneumothorax